Atai Life Sciences N.V. (ATAI) Stock Price, Quote & News

Company Profile

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 20 793 2536

Website: atai.com

Address:

Prof. J.H. Bavincklaan 7, Amstelveen, Netherlands

mwhite9869 Oct. 27 at 9:33 PM

$ATAI it's so dead calm. That's so weird....

0 · Reply

PsychedStocks Oct. 27 at 8:34 PM

$CYBN $CMPS $ATAI $MNMD $SPY

0 · Reply

VibinNchillin Oct. 27 at 8:12 PM

$ATAI the inevitable: Success

0 · Reply

stoxx0007 Oct. 27 at 8:01 PM

$ATAI= WTF happened here!! 😳

0 · Reply

Lewis_Vaughan Oct. 27 at 7:35 PM

$ATAI every time

0 · Reply

Mcahill Oct. 27 at 7:13 PM

$ATAI sick sick

0 · Reply

macrossluvsrobotech Oct. 27 at 6:43 PM

$CMPS NICE "I’m going to test psilocybin as a longevity therapy." https://x.com/bryan_johnson/status/1982826028641947819?s=46 $ATAI

2 · Reply

Cat666 Oct. 27 at 6:21 PM

$AVXL it’s not too late. Sell Anavex and buy $ATAI .. you are welcome.

1 · Reply

PistiMarv Oct. 27 at 5:56 PM

$ATAI Bought another 3000 shares, should we hope that tomorrow there will be positiv data

0 · Reply

Hanaleimike Oct. 27 at 5:35 PM

$ATAI someone is trying to hold this Down at 6

1 · Reply

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

Oct 20, 2025, 9:00 AM EDT - 7 days ago

Atai Life Sciences And Beckley Psytech: Promising Emerging Leader In Psychedelics

Oct 16, 2025, 10:31 PM EDT - 10 days ago

atai Life Sciences Announces Pricing of Public Offering of Common Shares

Oct 16, 2025, 4:12 PM EDT - 11 days ago

atai Life Sciences Announces Proposed Public Offering of Common Shares

Oct 16, 2025, 4:10 PM EDT - 11 days ago

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression

Oct 13, 2025, 2:21 PM EDT - 14 days ago

Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside

Oct 1, 2025, 2:40 PM EDT - 26 days ago

Atai Life Sciences: Still A Decent Prospect - But Only Just

Sep 23, 2025, 2:50 PM EDT - 4 weeks ago

Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients

Sep 23, 2025, 7:00 AM EDT - 4 weeks ago

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

Sep 9, 2025, 6:59 AM EDT - 6 weeks ago

Atai Life Sciences N.V. (ATAI) Presents at H.C.

Aug 28, 2025, 4:05 PM EDT - 2 months ago

atai Life Sciences to Participate in September Investor Conferences

Jul 28, 2025, 5:01 PM EDT - 3 months ago

Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus

Jul 28, 2025, 10:58 AM EDT - 3 months ago

Why Is ATAI Life Sciences Stock Trading Lower On Monday?

Jul 28, 2025, 8:13 AM EDT - 3 months ago

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session

RVTY

Jul 25, 2025, 4:16 PM EDT - 3 months ago

Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial

Jul 25, 2025, 4:05 PM EDT - 3 months ago

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Jul 2, 2025, 2:29 PM EDT - 4 months ago

Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD

Jul 1, 2025, 9:28 AM EDT - 4 months ago

Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data

Jul 1, 2025, 6:05 AM EDT - 4 months ago

atai Life Sciences Announces $50 Million Private Placement Financing

Jul 1, 2025, 6:00 AM EDT - 4 months ago

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

Jun 2, 2025, 6:00 AM EDT - 5 months ago

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

May 29, 2025, 8:30 AM EDT - 5 months ago

atai Life Sciences to Participate in Upcoming Investor Conferences

May 20, 2025, 7:00 AM EDT - 5 months ago

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

May 14, 2025, 7:00 AM EDT - 5 months ago

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 13, 2025, 7:01 AM EDT - 5 months ago

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

Mar 11, 2025, 7:00 AM EDT - 8 months ago

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

Feb 27, 2025, 12:45 PM EST - 8 months ago

Atai: Following The Path That Spravato Laid And Moving Beyond It

Feb 24, 2025, 4:10 PM EST - 8 months ago

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

Jan 29, 2025, 11:57 AM EST - 9 months ago

Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst

Jan 10, 2025, 7:00 AM EST - 10 months ago

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

Oct 2, 2024, 9:21 AM EDT - 1 year ago

IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG

Sep 4, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 2:00 PM EDT - 1 year ago

Psychedelic Stock Deep Dive: Atai Life Sciences

Aug 13, 2024, 7:10 AM EDT - 1 year ago

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 12, 2024, 12:12 PM EDT - 1 year ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

CMPS CYBN MNMD

Aug 7, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

Jun 26, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

Jun 20, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

May 31, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

May 15, 2024, 6:59 AM EDT - 1 year ago

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

Apr 24, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

Apr 17, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

Mar 28, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

Mar 27, 2024, 7:00 AM EDT - 1 year ago

atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

Mar 4, 2024, 8:00 AM EST - 1 year ago

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

Feb 28, 2024, 5:00 PM EST - 1 year ago

atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference

Feb 6, 2024, 5:00 PM EST - 1 year ago

atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

Jan 4, 2024, 7:00 AM EST - 1 year ago

atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

Nov 29, 2023, 6:55 PM EST - 2 years ago

Atai Life Sciences: A Promising Venture In The Psychedelic Therapy Market Trading Below Cash Value

mwhite9869 Oct. 27 at 9:33 PM

$ATAI it's so dead calm. That's so weird....

0 · Reply

PsychedStocks Oct. 27 at 8:34 PM

$CYBN $CMPS $ATAI $MNMD $SPY

0 · Reply

VibinNchillin Oct. 27 at 8:12 PM

$ATAI the inevitable: Success

0 · Reply

stoxx0007 Oct. 27 at 8:01 PM

$ATAI= WTF happened here!! 😳

0 · Reply

Lewis_Vaughan Oct. 27 at 7:35 PM

$ATAI every time

0 · Reply

Mcahill Oct. 27 at 7:13 PM

$ATAI sick sick

0 · Reply

macrossluvsrobotech Oct. 27 at 6:43 PM

$CMPS NICE "I’m going to test psilocybin as a longevity therapy." https://x.com/bryan_johnson/status/1982826028641947819?s=46 $ATAI

2 · Reply

Cat666 Oct. 27 at 6:21 PM

$AVXL it’s not too late. Sell Anavex and buy $ATAI .. you are welcome.

1 · Reply

PistiMarv Oct. 27 at 5:56 PM

$ATAI Bought another 3000 shares, should we hope that tomorrow there will be positiv data

0 · Reply

Hanaleimike Oct. 27 at 5:35 PM

$ATAI someone is trying to hold this Down at 6

1 · Reply

VibinNchillin Oct. 27 at 5:34 PM

$ATAI man! I love stable growth

0 · Reply

wmoller Oct. 27 at 4:00 PM

$ATAI The BPL-003 OLE data should be hitting this week (per Atai's recent guidance and its updated October investor deck). My money is on a pre-market release tomorrow morning (Tuesday, 10/28), but that's just a hunch.

0 · Reply

Hanaleimike Oct. 27 at 1:52 PM

$ATAI morning action seems to be a pattern.

1 · Reply

Schaf Oct. 27 at 12:25 PM

$ATAI not fully insulated from broad market sentiment, but with insane forward AI-driven valuations prevailing across the market, how could you NOT want to be long & deep into a well-run, diversified biotech with this momentum and a 50bn+ end market? It’s such a logical hedge, and yields no upside.

1 · Reply

twiggs462 Oct. 27 at 11:43 AM

$MNMD $ATAI - The Rise of Psychedelic Education: University Programs and Research Centers Expanding Across the U.S. This growing academic field is driven by renewed interest in the potential therapeutic benefits of psychedelics for mental health conditions such as depression and PTSD. The rapid growth of psychedelic education and research programs within major universities signals strong validation and long-term market potential for psychedelic therapies. As institutions invest in training workforce talent, building clinical infrastructure, and advancing groundbreaking studies, they are reducing regulatory barriers and accelerating commercialization timelines. This academic momentum strengthens the credibility of psychedelic science, expands the pool of qualified practitioners, and positions the sector for scalable clinical adoption—making it an increasingly compelling opportunity for investors seeking early exposure to the future of mental health treatment.

5 · Reply

Insayn Oct. 27 at 11:40 AM

$ATAI – Solid update ahead of closing ✅ New 8-K/425 confirms Beckley deal refinements: • Total shares to Beckley holders reduced by 1.22M (less dilution) 🔥 • Only 900k shares to Cantor Fitzgerald as advisor fee (no lock-up, minor short-term pressure) • Lock-ups for Beckley shareholders stay in place until after BPL-003 Phase 2b readout 🧠 • Cash preserved by using shares for transaction costs 💵 👉 Overall: Bullish structural update — fewer shares, cleaner terms, closing imminent. Big picture still intact: BPL-003 + redomicile = major catalysts into 2026. #ATAI #biotech #psychedelics #Beckley

0 · Reply

mwhite9869 Oct. 27 at 11:24 AM

$ATAI Price Update $14-$16 depending on the source.

0 · Reply

VibinNchillin Oct. 27 at 11:22 AM

$ATAI yay green!

0 · Reply

FLNY Oct. 27 at 11:21 AM

$ATAI

0 · Reply

FALCON765 Oct. 27 at 1:21 AM

$ATAI TARGET 14 NOW ! GOOD UPSIDE... % !

1 · Reply

Vynfred Oct. 27 at 12:24 AM

$ATAI $BTC.X Atai will capture some upside from the BTC jump, probably to a new ATH soon. March 2025, the company announced plans to adopt a Bitcoin treasury strategy, initially investing $5 million in BTC to offset long R&D cycles, combat inflation, and protect capital. As of March 31, 2025, ATAI held 58 BTC, valued at approximately $5 million at the time.

0 · Reply

JoeBrandon46 Oct. 26 at 8:08 PM

$ATAI Christian Angermayer interviewed on Friday, says this is a 50b+ company in 5 to 10 years, because soon enough psychadelics will be so widespread that people will use it preventatively and as a first form of treatment. Sky is the limit here gents. So he seems to think in 5 years this could be at 190$ SP. Insane!

2 · Reply

Market Cap	1.35B
Revenue (ttm)	310,000.00
Net Income (ttm)	-149.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-48,151.61%
Debt to Equity Ratio	0.00

Volume	8,581,341
Avg Vol	6,269,936
Day's Range	N/A - N/A
Shares Out	233.78M
Stochastic %K	31%
Beta	1.58
Analysts	Strong Sell
Price Target	$12.14